🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Massachusetts
Clinical trial register · United States · industry-sponsored

Clinical Trials in Massachusetts

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9110 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Sep 2026, 03:16 UTC
9110
Studies in scope
industry-sponsored, all four open statuses
4947
Recruiting now
open to new participants
2198
Lead sponsors
across recruiting studies
Top states
California 113 Florida 107 Massachusetts 65 Georgia 62 Illinois 59
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca70 Novartis Pharmaceuticals65 Eli Lilly and Company50 AbbVie40 Bristol-Myers Squibb34 Clear sponsor filter
State
California113 Florida107 Massachusetts65 Georgia62 Illinois59
All 47 states
Target enrolment
to
65 of 9110 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
NCT07811869Chronic Pruritus of Unknown Origin
Novartis Pharmaceuticals
Phase 3
180
Massachusetts
2026-10-06
Recruiting
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07441642Geographic Atrophy Secondary to Age-related Macular Degeneration
Novartis Pharmaceuticals
Phase 2
272
California, Florida, Massachusetts, New Jersey, New York, Pennsylvania, Texas
2026-03-09
Recruiting
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
NCT07006727Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
Novartis Pharmaceuticals
Phase 1
123
Iowa, Massachusetts, Michigan, Washington
2025-10-16
Recruiting
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
NCT07206056Progressive Metastatic Castrate Resistant Prostate Cancer
Novartis Pharmaceuticals
Phase 1/2
188
Colorado, Florida, Georgia, Kansas, Massachusetts, North Carolina, Ohio, Washington
2025-10-15
Recruiting
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
NCT07094516Alzheimer's Disease
Novartis Pharmaceuticals
Phase 2
407
Arizona, California, Florida, Hawaii, Kansas, Massachusetts, Missouri, Nevada
2025-08-07
Active, closed
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT06991556Metastatic Hormone-sensitive Prostate Cancer
Novartis Pharmaceuticals
Phase 2
168
California, Colorado, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan
2025-07-07
Active, closed
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07047118Prostatic Cancer, Castration-Resistant
Novartis Pharmaceuticals
Phase 2
138
California, Colorado, Connecticut, Indiana, Massachusetts, Nebraska, New York, Pennsylvania
2025-07-03
Recruiting
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
400
Arizona, California, District of Columbia, Florida, Illinois, Kansas, Maryland, Massachusetts
2025-06-23
Recruiting
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
NCT06947993Atopic Dermatitis
Novartis Pharmaceuticals
Phase 2
224
Alabama, Arkansas, California, District of Columbia, Florida, Georgia, Kentucky, Massachusetts
2025-05-16
Recruiting
A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.
NCT06632600Chagas Disease
Novartis Pharmaceuticals
Phase 2
130
California, Florida, Massachusetts, Texas
2025-04-28
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 1/2
280
California, Florida, Massachusetts, Missouri, New York, Tennessee, Texas, Washington
2025-04-03
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06840392Hidradenitis Suppurativa
Novartis Pharmaceuticals
Phase 3
565
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts
2025-03-20
Active, closed
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
NCT06868290ANCA Associated Vasculitis (AAV)
Novartis Pharmaceuticals
Phase 2
126
Colorado, Florida, Illinois, Massachusetts, Michigan, Minnesota, North Carolina, Oregon
2025-03-13
Recruiting
A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
NCT06952426Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Observational
300
Massachusetts
2025-03-04
Recruiting
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NCT06780670Prostate Cancer
Novartis Pharmaceuticals
Phase 2/3
443
California, Connecticut, Florida, Georgia, Indiana, Kansas, Louisiana, Massachusetts
2025-02-27
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920Generalized Myasthenia Gravis
Novartis Pharmaceuticals
Phase 3
180
Arizona, California, District of Columbia, Florida, Illinois, Maryland, Massachusetts, Michigan
2025-02-07
Active, closed
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
NCT06444113Multiple Sclerosis
Novartis Pharmaceuticals
Phase 4
24
California, Colorado, Illinois, Massachusetts
2024-11-25
Active, closed
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06655896Scleroderma, Diffuse
Novartis Pharmaceuticals
Phase 2
96
California, Florida, Illinois, Iowa, Massachusetts, Michigan, Minnesota, Ohio
2024-10-29
Recruiting
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
NCT06649110Healthy Volunteers, Pulmonary Arterial Hypertension
Novartis Pharmaceuticals
Phase 1/2
232
Arizona, California, Colorado, Florida, Georgia, Kansas, Kentucky, Massachusetts
2024-10-24
Active, closed
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
NCT06643481Amyotrophic Lateral Sclerosis (ALS)
Novartis Pharmaceuticals
Phase 2
251
California, Florida, Georgia, Kansas, Massachusetts, Nebraska, New York, North Carolina
2024-10-17
Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
162
Alabama, California, Florida, Massachusetts, Michigan, Minnesota, Texas, Washington
2024-10-15
Active, closed
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
NCT06581198Lupus Erythematosus, Systemic, Lupus Nephritis
Novartis Pharmaceuticals
Phase 2
179
Alabama, California, Illinois, Iowa, Kentucky, Massachusetts, Missouri, North Carolina
2024-09-04
Recruiting
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
NCT06546670Sickle Cell Disease
Novartis Pharmaceuticals
Phase 1/2
161
Alabama, Florida, Massachusetts, North Carolina, Pennsylvania, Rhode Island, Texas
2024-08-15
Active, closed
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
NCT06517758Generalized Myasthenia Gravis
Novartis Pharmaceuticals
Phase 3
146
Arizona, California, Georgia, Illinois, Maryland, Massachusetts, Michigan, North Carolina
2024-07-31
Active, closed
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
NCT05739942Newly Diagnosed and Recurrent Glioblastoma
Novartis Pharmaceuticals
Phase 1
42
California, Colorado, Massachusetts, New York, Ohio, Utah
2024-05-15
Recruiting
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
NCT05646381Aortic Stenosis
Novartis Pharmaceuticals
Phase 2
502
Alabama, California, Florida, Kansas, Massachusetts, Michigan, Minnesota, New Jersey
2024-03-07
Recruiting
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
NCT05948943Lymphatic Malformations
Novartis Pharmaceuticals
Phase 2/3
232
California, District of Columbia, Florida, Massachusetts, Missouri, North Carolina, Ohio, Oregon
2023-11-24
Active, closed
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
NCT05985915Sjogrens Syndrome
Novartis Pharmaceuticals
Phase 3
612
California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland, Massachusetts
2023-10-27
Recruiting
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
NCT05755386IC-MPGN
Novartis Pharmaceuticals
Phase 3
106
California, Colorado, Florida, Georgia, Massachusetts, Minnesota, Missouri, New Mexico
2023-10-02
Active, closed
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
NCT05885555Primary Immune Thrombocytopenia (ITP)
Novartis Pharmaceuticals
Phase 2
41
Massachusetts
2023-08-16
Active, closed
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
NCT05838768MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
Novartis Pharmaceuticals
Phase 1
123
California, Massachusetts, New York, Texas
2023-06-27
Active, closed
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
NCT05552469Myeloid Diseases
Novartis Pharmaceuticals
Phase 1
71
California, Florida, Illinois, Maryland, Massachusetts, Minnesota, New York, Tennessee
2023-05-08
Active, closed
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
NCT05653349Primary Immune Thrombocytopenia (ITP)
Novartis Pharmaceuticals
Phase 3
226
Arizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Massachusetts
2023-02-03
Active, closed
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
NCT05653219Primary Immune Thrombocytopenia
Novartis Pharmaceuticals
Phase 3
152
Arizona, Colorado, Illinois, Massachusetts, Michigan, Montana, New York
2023-02-02
Active, closed
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
Novartis Pharmaceuticals
Phase 1
126
Massachusetts, New York, Pennsylvania, Tennessee
2022-10-26
Active, closed
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT05358249KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 1/2
74
Massachusetts, New York
2022-10-24
Active, closed
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
NCT05349214Sjogren Syndrome
Novartis Pharmaceuticals
Phase 3
506
California, Florida, Georgia, Illinois, Kansas, Massachusetts, New Mexico, New York
2022-08-04
Active, closed
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
NCT05415072Metastatic Uveal Melanoma
Novartis Pharmaceuticals
Phase 1/2
66
Massachusetts, New York
2022-07-04
Active, closed
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
NCT05090371Relapsing-Remitting Multiple Sclerosis
Novartis Pharmaceuticals
Phase 4
136
Alabama, Arizona, California, Florida, Idaho, Louisiana, Maryland, Massachusetts
2022-03-02
Active, closed
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
NCT05230537Age-Related Macular Degeneration
Novartis Pharmaceuticals
Phase 2
170
California, Colorado, Florida, Indiana, Louisiana, Maryland, Massachusetts, New Jersey
2022-02-17
Active, closed
Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)
NCT04980833PIK3CA-related Overgrowth Spectrum (PROS)
Novartis Pharmaceuticals
Phase 2
41
Massachusetts
2022-01-27
Recruiting
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
NCT04925479Myeloid Leukemia, Philadelphia Positive
Novartis Pharmaceuticals
Phase 1/2
34
Indiana, Massachusetts, Mississippi, New York, Ohio, Pennsylvania, Texas, Utah
2021-12-27
Active, closed
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
NCT04940052Differentiated Thyroid Cancer (DTC)
Novartis Pharmaceuticals
Phase 3
153
Illinois, Massachusetts
2021-11-15
Active, closed
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
NCT04857372Mesothelioma
Novartis Pharmaceuticals
Phase 1
137
California, Illinois, Massachusetts, Ohio, Texas
2021-10-21
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Novartis Pharmaceuticals
Phase 3
405
Colorado, Florida, Kentucky, Massachusetts, North Carolina, Oregon, South Dakota, Tennessee
2021-10-06
Active, closed
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
NCT04557462Primary IgA Nephropathy
Novartis Pharmaceuticals
Phase 3
448
Arizona, California, Colorado, Idaho, Illinois, Maryland, Massachusetts, Minnesota
2021-09-20
Active, closed
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
NCT05067140Prostate Cancer Metastatic
Novartis Pharmaceuticals
Phase 1/2
164
California, Connecticut, Florida, Maryland, Massachusetts, Michigan, New York, Pennsylvania
2021-09-02
Recruiting
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
NCT04817618C3G
Novartis Pharmaceuticals
Phase 3
98
Colorado, Florida, Georgia, Indiana, Iowa, Maryland, Massachusetts, New Jersey
2021-07-28
Active, closed
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
NCT04689828Prostatic Neoplasms
Novartis Pharmaceuticals
Phase 3
469
Colorado, Florida, Louisiana, Massachusetts, Missouri, Nebraska, New York, North Carolina
2021-06-15
Active, closed
Atrasentan in Patients With Proteinuric Glomerular Diseases
NCT04573920IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease
Novartis Pharmaceuticals
Phase 2
103
California, Colorado, Louisiana, Massachusetts, Minnesota, Nevada, North Carolina, Texas
2021-03-15
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
Novartis Pharmaceuticals
Phase 1/2
344
Georgia, Massachusetts, Pennsylvania, Texas
2021-02-24
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
404
Alabama, California, Florida, Georgia, Illinois, Indiana, Kentucky, Massachusetts
2020-12-11
Active, closed
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
NCT04417621Melanoma
Novartis Pharmaceuticals
Phase 2
134
California, Florida, Massachusetts, Minnesota, New York, Pennsylvania, Texas
2020-10-30
Active, closed
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
Novartis Pharmaceuticals
Phase 4
163
Arizona, District of Columbia, Florida, Indiana, Maryland, Massachusetts, Minnesota, New York
2019-11-04
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
Novartis Pharmaceuticals
Phase 1/2
300
Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, New Jersey, New York
2019-09-18
Active, closed
Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
NCT03814746Sickle Cell Disease (SCD)
Novartis Pharmaceuticals
Phase 3
254
Georgia, Massachusetts, North Carolina, Tennessee, Texas
2019-07-26
Active, closed
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals
Phase 1/2
217
California, Florida, Illinois, Kansas, Massachusetts, Pennsylvania, Tennessee, Texas
2019-06-26
Active, closed
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
NCT03891953Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer
Novartis Pharmaceuticals
Phase 1
98
Massachusetts, Tennessee
2019-05-07
Active, closed
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
NCT03040973Advanced Solid Tumors Which Are cMET-dependent
Novartis Pharmaceuticals
Phase 2
29
Massachusetts
2017-07-04
Active, closed
Ribociclib (LEE011) Rollover Study for Continued Access
NCT02934568Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
Novartis Pharmaceuticals
Phase 2
22
Alabama, Massachusetts, Michigan, New York, Tennessee
2016-12-15
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,400
Arizona, California, Georgia, Illinois, Kansas, Massachusetts, Michigan, Minnesota
2015-11-02
Active, closed
Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer
NCT02393625ALK-positive NSCLC
Novartis Pharmaceuticals
Phase 1
57
Arizona, Massachusetts, Pennsylvania
2015-05-27
Active, closed
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
NCT02381886Advanced Malignancies That Harbor IDHR132 Mutations
Novartis Pharmaceuticals
Phase 1
166
Massachusetts, New York, Texas
2015-03-06
Active, closed
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
NCT01872260Breast Cancer
Novartis Pharmaceuticals
Phase 1/2
259
California, Florida, Massachusetts, Tennessee, Texas, Washington
2013-10-22
Active, closed
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
NCT01892722Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
240
Alabama, California, Florida, Massachusetts, Michigan, New Jersey, Pennsylvania, Utah
2013-07-26
Rows per page Showing 1–65 of 65
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-usa/state/massachusetts

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.